Wedbush Securities Inc. Has $1.44 Million Position in Lexicon Pharmaceuticals, Inc. (LXRX)

Wedbush Securities Inc. increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 65.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 87,640 shares of the biopharmaceutical company’s stock after buying an additional 34,586 shares during the period. Wedbush Securities Inc. owned approximately 0.08% of Lexicon Pharmaceuticals worth $1,442,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in LXRX. Norges Bank bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $12,582,000. Teachers Advisors LLC boosted its stake in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock worth $1,478,000 after buying an additional 27,378 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Lexicon Pharmaceuticals by 22.4% in the fourth quarter. Macquarie Group Ltd. now owns 68,431 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 12,531 shares during the period. Boston Advisors LLC boosted its stake in shares of Lexicon Pharmaceuticals by 9.0% in the first quarter. Boston Advisors LLC now owns 32,655 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 2,695 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Lexicon Pharmaceuticals by 33.3% in the first quarter. Candriam Luxembourg S.C.A. now owns 260,000 shares of the biopharmaceutical company’s stock worth $3,729,000 after buying an additional 65,000 shares during the period.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) opened at 14.62 on Friday. The stock’s 50 day moving average price is $16.17 and its 200 day moving average price is $15.41. The company’s market cap is $1.54 billion. Lexicon Pharmaceuticals, Inc. has a one year low of $13.41 and a one year high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $12 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The firm’s revenue was down 40.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.37) EPS. Equities analysts predict that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/12/wedbush-securities-inc-has-1-44-million-position-in-lexicon-pharmaceuticals-inc-lxrx.html.

LXRX has been the topic of a number of analyst reports. HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 3rd. BidaskClub upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 14th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $27.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply